P2RX7 and breast carcinoma: This group subsequently confirmed a role for P2X7 in this process, with the novel P2X7 antagonist, anthraquinone emodin, impairing the invasiveness of P2X7 positive MDA-MB-435s cells but not P2X7 negative human breast cancer MDA-MB-468 cells [299].